This paper is in the following e-collection/theme issue:

Viewpoints and Perspectives (7) Clinical Information and Decision Making (1633) Clinical Cancer Research (96) Patient-Reported Outcome Measures (PROMs) (325) Chemotherapy and Side Effects Management (81) Cancer and Clinical Trials (29) Participatory Cancer Care (105)

Published on in Vol 11 (2025)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/64611, first published .
Leveraging Patient-Reported Outcome Measures for Optimal Dose Selection in Early Phase Cancer Trials

Leveraging Patient-Reported Outcome Measures for Optimal Dose Selection in Early Phase Cancer Trials

Leveraging Patient-Reported Outcome Measures for Optimal Dose Selection in Early Phase Cancer Trials

Authors of this article:

Bill Byrom1 Author Orcid Image ;   Anthony Everhart1 Author Orcid Image ;   Paul Cordero2 Author Orcid Image ;   Chris Garratt3 Author Orcid Image ;   Tim Meyer4 Author Orcid Image
Article Authors Cited by Tweetations Metrics

Bill Byrom   1 , PhD ;   Anthony Everhart   1 , MD ;   Paul Cordero   2 , PhD ;   Chris Garratt   3 , MBChB ;   Tim Meyer   4 , MBBS, PhD

1 Science and Medicine, Signant Health, Blue Bell, PA, United States

2 Patient Informed Development & Health Value Translation, Sanofi Pharmaceuticals, Reading, United Kingdom

3 New Medicines Development, Orion Pharma, Nottingham, United Kingdom

4 Research Department of Oncology, University College London, London, United Kingdom

Corresponding Author: